The Role of Mometasone Furoate Aqueous Nasal Spray in the Treatment of Adenoidal Hypertrophy in the Pediatric Age Group: Preliminary Results of a Prospective, Randomized Study
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
OBJECTIVE. We evaluated the efficacy of mometasone furoate aqueous nasal spray in decreasing adenoid size and reducing the severity of chronic nasal obstruction symptoms in children affected by adenoidal hypertrophy. METHODS. Sixty children were recruited in a 2-stage, randomized, placebo-controlled trial. All patients complained of chronic nasal obstruction symptoms, and nasal endoscopy showed >75% choanal obstruction attributable to adenoid pads. In the first stage, 30 patients (group A) underwent mometasone treatment (50 μg per nostril per day) for 40 days, and 30 children (group B) received placebo. In the second stage, at the end of the first 40-day treatment period, patients in group A who showed subjective and objective clinical improvement were divided into 2 subgroups; group A1 (11 children) received topical intranasal steroid treatment on alternate days for the first 2 weeks per month, whereas group A2 (10 children) continued daily mometasone treatment for the first 2 weeks per month. After 3 months, all children were reassessed. RESULTS. Fifty-seven children completed the study according to the protocol. After the first treatment period, the severity of symptoms and adenoid size decreased for 21 patients (77.7%) in group A. No improvement was observed in the placebo group. After 3 months of additional therapy, group A2 patients demonstrated a more-pronounced reduction in adenoid size compared with group A1 patients. No statistically significant change in symptoms was identified. Mometasone treatment was well tolerated by all patients. CONCLUSIONS. Mometasone furoate aqueous nasal spray may be considered useful in decreasing adenoid pad size and the severity of symptoms related to adenoidal hypertrophy. Children with adenoidal hypertrophy that is not associated with tonsillar hypertrophy should be considered for intranasal mometasone treatment before surgery is planned.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Efficacy of fluticasone nasal spray for pediatric obstructive sleep apnea
Brouillette, R. T., Manoukian, J. J., Ducharme, F. M., Oudjhane, K., Earle, L. G., Ladan, S., & Morielli, A. (2001) · The Journal of Pediatrics · doi:10.1067/mpd.2001.114474 · Cited by 396 · cited 2×
“Among several commercially available steroid nasal sprays (beclomethasone dipropionate, budesonide, flunisolide, fluticasone propionate, MF, and triamcinolone acetonide), we chose to test MF for 4 reasons, namely, (1) the drug had been reported previously not to cause any adverse tissue changes in the nasal mucosa of…”
MethodCassano, P., Gelardi, M., Cassano, M., Fiorella, M. L., & Fiorella, R. (2003) · International Journal of Pediatric Otorhinolaryngology · doi:10.1016/j.ijporl.2003.07.018 · Cited by 286
Craig, T. J., Teetsb, S., Lehman, E. B., Chinchilli, V. M., & Zwillich, C. (1998) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(98)70171-x · Cited by 249
Minshall, E., Ghaffar, O., Cameron, L., O'Brien, F., Quinn, H., Rowe‐Jones, J., Davies, R. J., Prior, A., Lund, V. J., Mackay, I. S., et al. (1998) · Otolaryngology–Head and Neck Surgery · doi:10.1177/019459989811800514 · Cited by 162
Cited by
Diagnosis and Management of Childhood Obstructive Sleep Apnea Syndrome
Marcus, C. L., Brooks, L. J., Draper, K. A., Gozal, D., Halbower, A. C., Jones, J., Schechter, M. S., Sheldon, S. H., Spruyt, K., Ward, S. D., et al. (2012) · Pediatrics · doi:10.1542/peds.2012-1671 · Cited by 2,432
Diagnosis and Management of Childhood Obstructive Sleep Apnea Syndrome
Marcus, C. L., Brooks, L. J., Ward, S. D., Draper, K. A., Gozal, D., Halbower, A. C., Jones, J., Lehmann, C., Schechter, M. S., Sheldon, S., et al. (2012) · Pediatrics · doi:10.1542/peds.2012-1672 · Cited by 1,680
The diagnosis and management of rhinitis: An updated practice parameter
WALLACE, D., DYKEWICZ, M., BERNSTEIN, D., BLESSINGMOORE, J., COX, L., KHAN, D., LANG, D., NICKLAS, R., OPPENHEIMER, J., & PORTNOY, J. (2008) · Journal of Allergy and Clinical Immunology · doi:10.1016/j.jaci.2008.06.003 · Cited by 1,096
Obstructive sleep disordered breathing in 2- to 18-year-old children: diagnosis and management
Kaditis, A. G., Alonso Alvarez, M. L., Boudewyns, A., Alexopoulos, E. I., Ersu, R., Joosten, K., Larramona, H., Miano, S., Narang, I., Trang, H., et al. (2016) · European Respiratory Journal · doi:10.1183/13993003.00385-2015 · Cited by 908
Pediatric Obstructive Sleep Apnea: Complications, Management, and Long-term Outcomes
Capdevila, O. S., Kheirandish-Gozal, L., Dayyat, E., & Gozal, D. (2008) · Proceedings of the American Thoracic Society · doi:10.1513/pats.200708-138mg · Cited by 440
Intranasal Budesonide Treatment for Children With Mild Obstructive Sleep Apnea Syndrome
Kheirandish-Gozal, L., & Gozal, D. (2008) · Pediatrics · doi:10.1542/peds.2007-3398 · Cited by 272
Zhang, L., Mendoza-Sassi, R. A., César, J. A., & Chadha, N. K. (2008) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006286.pub2 · Cited by 114
Liming, B. J., Ryan, M., Mack, D., Ahmad, I., & Camacho, M. (2019) · Otolaryngology–Head and Neck Surgery · doi:10.1177/0194599818815683 · Cited by 99
Chohan, A., Lal, A., Chohan, K., Chakravarti, A., & Gomber, S. (2015) · International Journal of Pediatric Otorhinolaryngology · doi:10.1016/j.ijporl.2015.07.009 · Cited by 86
Non‐surgical treatment of adenoidal hypertrophy: The role of treating IgE‐mediated inflammation
Scadding, G. (2010) · Pediatric Allergy and Immunology · doi:10.1111/j.1399-3038.2010.01012.x · Cited by 72
“Berlucchi and colleagues (4) randomized 60 children (3–7 yr of age) with symptoms of chronic nasal obstruction and AH occluding ‡75% of the nasopharynx to mometasone furoate aqueous nasal spray (MFNS) 100 lg/day (50 lg/spray) or placebo.”
BackgroundInfluentialBhargava, R., & Chakravarti, A. (2014) · American Journal of Otolaryngology · doi:10.1016/j.amjoto.2014.06.006 · Cited by 50
Metadata
- Authors
- Berlucchi, M., Salsi, D., Valetti, L., Parrinello, G., & Nicolai, P.
- Venue
- Pediatrics
- Publisher
- American Academy of Pediatrics (AAP)
- Published
- 2007-06-01
- Volume
- 119
- Issue
- 6
- Pages
- e1392-e1397
- ISSN
- 0031-4005 (ISSN-L)
- 1098-4275
- OpenAlex
- W1979933646
- Cited by
- 133
- References
- 4
- FWCI
- 9.78
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.